THE NEW BEVACIZUMAB BIOSIMILAR FROM CLONMEL HEALTHCARE
SIMPLY CONVINCING: OYAVAS® IS CONFIRMED TO BE A BIOSIMILAR TO THE REFERENCE PRODUCT*
With an amino acid sequence highly similar to that of the reference product,* the biosimilarity
of Oyavas® was demonstrated according to EMA recommendations and guidelines
Similar molecular mass
Similar protein conformation
Similar glycan attachment site
Similar distribution of glycans
Similar charge variants profile
Similar affinity for VEGF
Similar PK profile
*Avastin® (bevacizumab) 1. Oyavas® EPAR Public Assessment Report. Available at: https://www.ema.europa.eu/en/documents/ assessment-report/oyavas-epar-public-assessment-report_en.pdf. Last accessed May 2021.
Oyavas® is indicated across 6 cancer types and offers a more affordable alternative to the reference product
* † 1
With €1.2 billion spent on the reference product* in Europe, the use of bevacizumab biosimilars could mean a saving of €360 million for healthcare systems
*Avastin® (bevacizumab) †Cost of Oyavas® and reductions in price will vary depending on the market ‡Assuming a 30% average price discount 1. Oyavas® SmPC (Apr. 2021). 2. Data on file. Internal calculations by STADA based on IQVIA MIDAS data for Bevacizumab non-generic products. MAT 09/2020 sales values in EUR/MNF for Europe: EU27 (w/o CY+MT)+CH+NO+RS+RU+UK. 3. Konstantinidou S et al. Oncol Lett 2020;19:45–51.
Clonmel Healthcare is a member of the STADA GROUP, a trusted partner with over 20 years of experience in biosimilars. We are committed to increasing patient access to quality, affordable medicines by expanding our portfolio of biosimilars over the coming years.
1 STADA founded Bioceuticals Arzneimittel AG in 2000
STADA BIOSIMILARS: EXPECT A MASTERPIECE
When heritage and innovation meet, science becomes an art
Similar to the reference product in
terms of efficacy, safety and quality
Cost-effective, affordable prices
compared to the reference product
Due to their cost advantage, modern biosimilars increase the availability of reliable treatments
ACCESS TO AFFORDABLE TREATMENT REMAINS
A CONCERN FOR MANY PATIENTS
Globally, many patients
remain unable to
access the treatments
patients access to these
treatments, costing less than the reference product
1. Konstantinidou S et al. Oncol Lett 2020;19:45–51. 2. World Health Organization. Geneva, 2018. Pricing of cancer medicines and its impacts. Licence: CC BY-NC-SA 3.0 IGO. Available at: https://apps.who.int/iris/handle/10665/277190. Last accessed May 2021. 3. IQVIA 2018. The impact of biosimilar competition in Europe. Available at: https://ec.europa.eu/docsroom/documents/31642/attachments/1/translations/en/renditions/native. Last accessed May 2021.